Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 32

    1.

    Testosterone promotes DNA damage response under oxidative stress in prostate cancer cell lines.

    Ide H, Lu Y, Yu J, China T, Kumamoto T, Koseki T, Yamaguchi R, Muto S, Horie S.

    Prostate. 2012 Jan 30. doi: 10.1002/pros.22492. [Epub ahead of print]

    PMID:
    22290195
    [PubMed - as supplied by publisher]
    2.

    HDAC inhibitor MS-275 attenuates the inflammatory reaction in rat experimental autoimmune prostatitis.

    Zhang ZY, Schluesener HJ.

    Prostate. 2012 Jan;72(1):90-9. doi: 10.1002/pros.21410. Epub 2011 May 2.

    PMID:
    21538420
    [PubMed - indexed for MEDLINE]
    3.

    TGF-β1-induced EMT of non-transformed prostate hyperplasia cells is characterized by early induction of SNAI2/Slug.

    Slabáková E, Pernicová Z, Slavíčková E, Staršíchová A, Kozubík A, Souček K.

    Prostate. 2011 Sep;71(12):1332-43. doi: 10.1002/pros.21350. Epub 2011 Feb 14.

    PMID:
    21321977
    [PubMed - indexed for MEDLINE]
    4.

    Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy.

    Niu Y, Ge R, Hu L, Diaz C, Wang Z, Wu CL, Olumi AF.

    Prostate. 2011 Sep;71(12):1317-24. doi: 10.1002/pros.21348. Epub 2011 Feb 9.

    PMID:
    21308715
    [PubMed - indexed for MEDLINE]
    5.

    Parathyroid hormone is not involved in prostate growth in patients with benign prostatic hyperplasia.

    Kim WT, Choi YD, Park C, Kim YW, Yun SJ, Kim IY, Kim WJ.

    Prostate. 2011 Aug 1;71(11):1210-5. doi: 10.1002/pros.21336. Epub 2011 Jan 12.

    PMID:
    21656831
    [PubMed - indexed for MEDLINE]
    6.

    An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate.

    Haverkamp JM, Charbonneau B, Crist SA, Meyerholz DK, Cohen MB, Snyder PW, Svensson RU, Henry MD, Wang HH, Ratliff TL.

    Prostate. 2011 Aug 1;71(11):1139-50. doi: 10.1002/pros.21327. Epub 2011 Jan 12.

    PMID:
    21656824
    [PubMed - indexed for MEDLINE]
    7.

    Testosterone and prolactin increase carboxypeptidase-D and nitric oxide levels to promote survival of prostate cancer cells.

    Thomas LN, Morehouse TJ, Too CK.

    Prostate. 2012 Mar;72(4):450-60. doi: 10.1002/pros.21446. Epub 2011 Jun 17.

    PMID:
    21688280
    [PubMed - indexed for MEDLINE]
    8.

    Anti-angiogenic effects and mechanism of prazosin.

    Liao CH, Guh JH, Chueh SC, Yu HJ.

    Prostate. 2011 Jun 15;71(9):976-84. doi: 10.1002/pros.21313. Epub 2010 Dec 6.

    PMID:
    21541974
    [PubMed - indexed for MEDLINE]
    9.

    Internal prostatic architecture on transrectal ultrasonography predicts future prostatic growth: natural history of prostatic hyperplasia in a 15-year longitudinal community-based study.

    Fukuta F, Masumori N, Mori M, Tsukamoto T.

    Prostate. 2011 May;71(6):597-603. doi: 10.1002/pros.21275. Epub 2010 Oct 13.

    PMID:
    20945406
    [PubMed - indexed for MEDLINE]
    10.

    Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer.

    Chiriva-Internati M, Yu Y, Mirandola L, D'Cunha N, Hardwicke F, Cannon MJ, Cobos E, Kast WM.

    Prostate. 2012 Jan;72(1):12-23. doi: 10.1002/pros.21400. Epub 2011 Apr 25.

    PMID:
    21520158
    [PubMed - indexed for MEDLINE]
    11.

    Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia.

    Robert G, Smit F, Hessels D, Jannink S, Karthaus HF, Aalders T, Jansen K, de la Taille A, Mulders PF, Schalken JA.

    Prostate. 2011 Nov;71(15):1701-9. doi: 10.1002/pros.21387. Epub 2011 Mar 28.

    PMID:
    21446005
    [PubMed - indexed for MEDLINE]
    12.

    VAT-1 is a novel pathogenic factor of progressive benign prostatic hyperplasia.

    Mori F, Tanigawa K, Endo K, Minamiguchi K, Abe M, Yamada S, Miyoshi K.

    Prostate. 2011 Mar 10. doi: 10.1002/pros.21374. [Epub ahead of print]

    PMID:
    21394740
    [PubMed - as supplied by publisher]
    13.

    Effect of a phytotherapeutic agent, Eviprostat®, on prostatic and urinary cytokines/chemokines in a rat model of nonbacterial prostatitis.

    Sugimoto M, Oka M, Tsunemori H, Yamashita M, Kakehi Y.

    Prostate. 2011 Mar 1;71(4):438-44. doi: 10.1002/pros.21299. Epub 2010 Oct 28.

    PMID:
    21254154
    [PubMed - indexed for MEDLINE]
    14.

    Parathyroid hormone is not involved in prostate growth in patients with benign prostatic hyperplasia.

    Kim WT, Choi YD, Park C, Kim YW, Yun SJ, Kim IY, Kim WJ.

    Prostate. 2011 Jan 12. [Epub ahead of print]

    PMID:
    21229562
    [PubMed - as supplied by publisher]
    15.

    Elevated expression of cancer-associated proliferating cell nuclear antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer.

    Wang X, Hickey RJ, Malkas LH, Koch MO, Li L, Zhang S, Sandusky GE, Grignon DJ, Eble JN, Cheng L.

    Prostate. 2011 May 15;71(7):748-54. doi: 10.1002/pros.21291. Epub 2010 Oct 28.

    PMID:
    21031434
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    16.

    LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.

    Rick FG, Schally AV, Block NL, Halmos G, Perez R, Fernandez JB, Vidaurre I, Szalontay L.

    Prostate. 2011 May 15;71(7):736-47. doi: 10.1002/pros.21289. Epub 2010 Oct 13.

    PMID:
    20945403
    [PubMed - indexed for MEDLINE]
    17.

    The effect of estrogen supplementation on cell proliferation and expression of c-kit positive cells in the rat prostate.

    Kusljic S, Exintaris B.

    Prostate. 2010 Oct 1;70(14):1555-62.

    PMID:
    20687229
    [PubMed - indexed for MEDLINE]
    18.

    Muscarinic receptors and their mRNAs in type 2 Goto-Kakizaki diabetic rat prostate.

    Saito M, Kazuyama E, Shimizu S, Dimitriadis F, Kinoshita Y, Masuda E, Yamada S, Satoh K.

    Prostate. 2010 Oct 1;70(14):1533-9.

    PMID:
    20687226
    [PubMed - indexed for MEDLINE]
    19.

    Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix.

    Rozsa B, Nadji M, Schally AV, Dezso B, Flasko T, Toth G, Mile M, Block NL, Halmos G.

    Prostate. 2011 Apr;71(5):445-52. doi: 10.1002/pros.21258. Epub 2010 Sep 21.

    PMID:
    20859992
    [PubMed - indexed for MEDLINE]
    20.

    A transcriptional signature associated with the onset of benign prostate hyperplasia in a canine model.

    Gallardo-Arrieta F, Doll A, Rigau M, Mogas T, Juanpere N, García F, Morote J, Nuñez F, Abal M, Lloreta J, Reventós J.

    Prostate. 2010 Sep 15;70(13):1402-12.

    PMID:
    20687213
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk